Search Results - Shelonitda Rose

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure by Philippe Armand, Margaret A. Shipp, Vincent Ribrag, Jean‐Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen Snyder, Alejandro D. Ricart, Arun Balakumaran, Shelonitda Rose, Craig H. Moskowitz

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts

    Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts by Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srđan Verstovšek, Shelonitda Rose, Jun Zhang, Oumar Sy, Ruben A. Mesa

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

    Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis by Animesh Pardanani, Ayalew Tefferi, Tamás Masszi, Elena Mishchenko, Mark W. Drummond, Éric Jourdan, Alessandro M. Vannucchi, Mindaugas Jurgutis, Vincent Ribrag, Alessandro Rambaldi, Liang Piu Koh, Shelonitda Rose, Jun Zhang, Claire Harrison

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) by Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian, Amy O. Johnson‐Levonas, Craig Fancourt, Raymond W. Lam, Mary Jones, Clayton D. Knox, Shelonitda Rose, Payal Patel, Raoul Tibes

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

    Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors by Andrew J. Wagner, Udai Banerji, Amit Mahipal, Neeta Somaiah, Heather A. Hirsch, Craig Fancourt, Amy O. Johnson‐Levonas, Raymond W. Lam, Amy Meister, Giuseppe Lo Russo, Clayton D. Knox, Shelonitda Rose, David S. Hong

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

    Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML... by Amer M. Zeidan, James D. Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac W. Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, C.L. Beach, Lewis R. Silverman

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure

    Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure by Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Éric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srđan Verstovšek, Shelonitda Rose, Juan Shen, Tymara Berry, Carrie Brownstein, Ruben A. Mesa

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

    Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months by Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke, Daphne de Jong, Efraim H. Rosenberg, Serena Marchetti, Dick Pluim, Erik van Werkhoven, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, Jos H. Beijnen, Jan H.M. Schellens

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML by Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa Hasle, Andrzej Hellmann, David Taussig, Mar Tormo, Maria Teresa Voso, James D. Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes by Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa Hasle, K. OGASAWARA, James D. Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia‐Manero

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

    Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis by Aaron T. Gerds, Claire Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Alessandro M. Vannucchi, Rami S. Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam J. Mead, Jason Gotlib, Shelonitda Rose, Fabián Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

    Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors by Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick, Raoul Tibes, Lee Rosen, Albiruni Ryan Abdul Razak, Raymond W. Lam, Tim Demuth, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, Stuart D. Shumway, Li Liang, Amit M. Oza, Jan H.M. Schellens, Geoffrey I. Shapiro

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer

    A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer by Amit M. Oza, Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I. Weberpals, Robert M. Wenham, Naomi Laing, Michaël Tracy, Tomoko Freshwater, Mark A. Lee, Liu Ji, Jingjun Qiu, Shelonitda Rose, Eric H. Rubin, Kathleen N. Moore

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Supplementary material and tables from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive &lt;i&gt;TP53&lt;/i&gt;-mutant Ovarian Cancer

    Supplementary material and tables from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive &l... by Amit M. Oza, Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I. Weberpals, Robert M. Wenham, Naomi Laing, Michaël Tracy, Tomoko Freshwater, Mark A. Lee, Liu Ji, Jingjun Qiu, Shelonitda Rose, Eric H. Rubin, Kathleen N. Moore

    Published 2023
    Get full text Get full text
    Pré-impressão
    Save to List
    Saved in:
  15. 15
    Supplementary material and tables from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive &lt;i&gt;TP53&lt;/i&gt;-mutant Ovarian Cancer

    Supplementary material and tables from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive &l... by Amit M. Oza, Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, Marcia Hall, Frederik Marmé, Diane Provencher, Denise Uyar, Johanne I. Weberpals, Robert M. Wenham, Naomi Laing, Michaël Tracy, Tomoko Freshwater, Mark A. Lee, Liu Ji, Jingjun Qiu, Shelonitda Rose, Eric H. Rubin, Kathleen N. Moore

    Published 2023
    Get full text Get full text
    Pré-impressão
    Save to List
    Saved in:
  16. 16
    Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

    Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndro... by Guillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Rami S. Komrokji, Jake Shortt, David Valcárcel, Anna Jonášová, Sophie Dimicoli‐Salazar, Ing Soo Tiong, Chien‐Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Jeevan K. Shetty, Sheida Hayati, Sadanand Vodala, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Matteo Giovanni Della Porta

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: